The Multiple Myeloma Research Consortium (MMRC) collaboration is evaluating the preclinical activity of SNS-032 in multiple myeloma-relevant models and in primary disease tissue, extending non-clinical studies performed by Sunesis. Data from these studies will facilitate the identification of relevant mechanism-based biomarkers of patient response to SNS-032 and may guide rational combination strategies in planned clinical trials of SNS-032 in multiple myeloma.
Daniel Adelman, senior vice president, development and chief medical officer of Sunesis, said: “We are excited to be working with the MMRC and world-renowned researchers in further elucidating the potential of SNS-032 for the treatment of multiple myeloma. This collaboration is providing us with access to cutting-edge disease models, and the resulting data should further define SNS-032’s mechanism of action and the compound’s potential benefits in this patient population.”